Vera Therapeutics announced its management team will participate in a fireside chat and investor meetings at the Guggenheim 3rd Annual Healthcare Innovation Conference in Boston from November 9-11, 2026. The event will feature discussions on the company's focus on autoimmune disease treatments, including their flagship product TRUTAKNA™. A replay of the fireside chat will be available for 90 days on Vera Therapeutics' website. This participation highlights the company's ongoing efforts to engage investors and showcase its innovations in biotechnology.
Vera Therapeutics' participation in the Guggenheim Healthcare Innovation Conference is presented here with a snapshot of the health sector on Pluang as of Nov 02, 2026 19:21 WIB. Among 150 priced health-sector US stocks, 82 rose and 47 fell today. Notably, FLNA (Cassava Sciences Inc) gained 6.11% to USD 0.66 with a typical hold time of 39 days, contrasting with DNA (Ginkgo Bioworks Holdings Inc) at USD 11.79, up 4.99%, but held typically for only 9 days, while ALMS (Alumis Inc.) rose 4.45% to USD 7.04 with an 18-day hold time.
The global bio-based construction polymer market, valued at $18.2 billion in 2025, is projected to grow to $35 billion by 2033 at an 8.3% CAGR. Growth is fueled by rising demand for sustainable building materials that reduce greenhouse gas emissions ...
Annual Over-the-Air (OTA) software updates for software-defined vehicles (SDVs) are projected to reach over 2 billion globally by 2035, up from 546 million in 2025, driven by rising SDV sales and advanced vehicle software platforms. Level 3 and above...
Fram Wind Solutions AS, a joint venture partly owned by BW Offshore, secured a NOK 1.94 billion grant from Enova to develop a floating offshore wind project featuring two 18.5 MW turbines, the largest globally, with a combined capacity of 37 MW. The ...
Thailand's textile market is projected to grow from USD 4.97 billion in 2026 to USD 5.39 billion by 2032, at a CAGR of 1.31%. Growth is fueled by domestic fiber production, machinery upgrades, and rising demand for faster garment replenishment, espec...
Callan JMB has received and will install a QuickStrip™ oral thin-film production line from Rapid Dose Therapeutics at its Texas facility, marking a key step in expanding its domestic pharmaceutical manufacturing. This new capability aims to produce f...
